Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Science (New York, N.Y.)|November 6, 2004
Uridine addition after microRNA-directed cleavageBinzhang Shen, Howard M GoodmanPlant Physiology|January 26, 2008
Characterization of the monoterpene synthase gene tps26, the ortholog of a gene induced by insect herbivory in maizeChangfa Lin, Binzhang Shen, Zhennan Xu, et al.Nature Food|May 2, 2023
Improved performance of Eimeria-infected chickens fed corn expressing a single-domain antibody against interleukin-10Philip A Lessard, Matthew Parker, Oleg Bougri, et al.Plos One|June 1, 2012
A predictive model of intein insertion site for use in the engineering of molecular switchesJames Apgar, Mary Ross, Xiao Zuo, et al.Nature Biotechnology|October 23, 2012
Engineering a thermoregulated intein-modified xylanase into maize for consolidated lignocellulosic biomass processingBinzhang Shen, Xueguang Sun, Xiao Zuo, et al.Plos One|May 4, 2022
BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activityTaylor L Hickman, Eugene Choi, Kathleen R Whiteman, et al.Molecular Cancer Therapeutics|May 6, 2025
CRISPR screens identify POLB as a synthetic lethal enhancer of PARP inhibition exclusively in BRCA-mutated tumorsKatherine Lazarides, Justin L Engel, Michele Meseonznik, et al.Molecular Cancer Therapeutics|January 27, 2025
LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant CancersLauren Catherine M Martires, Leanne G Ahronian, Charlotte B Pratt, et al.Cell Reports Methods|June 1, 2026
Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screensSilvia Fenoglio, Yi Yu, James Tepper, et al.Molecular Cancer Therapeutics|January 31, 2025
Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination DeficiencyAntoine Simoneau, Charlotte B Pratt, Hsin-Jung Wu, et al.Pageof 2